Adamas Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2021 was $143.98 Mil.
During the past 12 months, Adamas Pharmaceuticals's average Total Assets Growth Rate was 51.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 42.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.80% per year.
During the past 9 years, Adamas Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 262.70%. The lowest was -31.00%. And the median was 22.60%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Adamas Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adamas Pharmaceuticals (NAS:ADMS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2021) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Adamas Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2021 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Adamas Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMS has been successfully added to your 